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related cost-effectiveness studies on diabetes. METHODS: A
literature search using PubMed and OhioLINK websites was
conducted for cost-effectiveness studies. The key terms used for
literature search were “diabetes”, and “cost, cost-effectiveness,
cost-beneﬁt, economics, or treatment outcome”. Eligible studies
were randomized controlled trials focusing cost-effectiveness of
diabetes drug therapies, published in English between July 2005
and October 2007. Review articles were excluded. RESULTS:
Initial search resulted in 911 abstracts. After applying the
inclusion/exclusion criteria, 11 studies were selected from
Canada, UK, USA, Austria, Germany and Asian regions. The
median sample size was 638 patients; the median duration of
trials was 39 weeks. Most studies demonstrated overall positive
effects in economic outcomes and found that interventions
improved the cost-effectiveness and health care utilization over
the control groups from their individual perspectives. Four
studies focused on insulin glargine, which together with other
new drugs including insulin detemir, exenatide and rosiglita-
zone can be more cost-effective. With regard to diabetes-related
complications such as renal disease, hypertension and diabetic
peripheral neuropathic pain, these studies suggest that the
earlier introduction of preventive measures such as therapeutic
drugs would lead to longer delays in the onset of its compli-
cations and the overall savings in health care resource utiliza-
tion. CONCLUSION: There is growing evidence that these
drug interventions may promote diabetic health with better
economic outcomes. The review complemented our previous
study of cost on diabetes till July 2005. Future research should
include extensive database search including databases such as
Cochran and manual search for the journals’ Diabetes, and
Diabetes Care.
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OBJECTIVE: Bradycardia-tachycardia syndrome (BTS) manage-
ment includes bradycardia and tachyarrhythmia therapy. Right
atrial appendage pacing (RAA), a typical pacing site, manages
bradycardia but have poor AF preventive properties. Biatrial
pacing (BiA) is a modality of pacing to prevent AF in BRT
patients with interatrial conduction disturbances. It is a cost-
effectiveness analysis of BiA versus RAA pacing in AF preven-
tion, in BTS patients. METHODS: Follow-up study: 125 pts (51
males, mean age = 67.9) with BTS, P-wave >120 ms and parox-
ysmal, recurrent AF; 50 pts had BiA and 75 RAA pacing system
implanted. Observation window was one year before pacemaker
implantation to three years after. Costs were calculated from the
public health care payer perspective. Primary clinical endpoints:
chronic AF occurrence and patient reported outcome reﬂecting
symptomatic AF episodes frequency at four point scale. AF epi-
sodes were deﬁned very frequent in case of AF episodes >1 per
week (rank 3), recurrent AF = 1 episode per week to 1 episode
per month (rank 2), occasional = if occurred <1 per month (rank
1), no recurrences = rank 0. Conﬁdence intervals for CER by
bootstrap method. RESULTS: The frequency of symptomatic AF
episodes decreased in BiA group as measured on the scale (2.54
vs 1.28; p < 0.001) and not in the RAA group (1.33 vs 1.55; NS).
There was 71.2% reduction of annual number of hospitaliza-
tions in BiA group; no change in RAA group as compared to
pre-implantation period. In BiA group 12.0% of patients devel-
oped chronic AF; 17.3% in the RAA group (NS). Incremental
cost-effectiveness ratio for decrease of AF frequency episodes
(BiA vs RAA) was 499.97 USD PPP (95%CI—272.5–1353.6) for
one point on the scale. CONCLUSION: Biatrial pacing in
contrast to RAA pacing decreases symptomatic AF episodes
frequency and hospitalizations. BiA compared to RAA pacing is
a cost-effective method of AF prevention in BTS patients with
pacing indications.
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OBJECTIVE: To assess whether bosentan is a cost-effective
ﬁrst-line treatment option compared with epoprostenol and
with no active intervention, all added to palliative care, for
patients with pulmonary arterial hypertension (PAH) of WHO
functional class (FC) III in the UK. METHODS: A cost-utility
model was constructed to simulate hypothetical patients with
PAH. Patients were assumed either to remain in FC III until
death or to deteriorate to FC IV where epoprostenol and pal-
liative care would be prescribed until death. It was further
assumed that the choice of ﬁrst-line treatment would not affect
the time to death, but instead would affect the duration patients
spend in FC IV. The time to deterioration in FC was approxi-
mated by time to clinical worsening (TTCW), a composite
measure of death or worsening of PAH leading to a change in
treatment. Data on TTCW was estimated from over three years
of observational data for bosentan and from published epide-
miological literature for palliative care alone. For epoprostenol,
TTCW was assumed equal to that of bosentan—in accordance
with published literature. The time horizon was that of patient
lifetime with only direct medical costs considered. The utility
associated with each FC was taken from published literature.
Costs and beneﬁts were discounted at 3.5% per annum. Proba-
bilistic sensitivity analyses were undertaken. RESULTS: Bosen-
tan dominated epoprostenol, as it provided the same number of
QALYs at a reduced cost. Bosentan dominated no active inter-
vention, as it had lower costs and greater QALYs, due to the
reduced time, per patient, spent in FC IV. CONCLUSION:
Bosentan is a more cost-effective ﬁrst-line therapy for patients
with PAH FC III in the UK than either epoprostenol or no active
intervention. It can be inferred that bosentan would also domi-
nate any other intervention with a TTCW not proven to be
better than palliative care alone.
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OBJECTIVE: To estimate differences in the efﬁcacy and safety of
rivaroxaban versus fondaparinux, warfarin and dabigatran in
prevention of venous thromboembolism (VTE). Such differences
may inﬂuence the cost-effectiveness of thromboprophylaxis
following total hip replacement (THR) or total knee replacement
(TKR). METHODS: Three large, randomized controlled trials
(RCTs; RECORD1–3) demonstrated relative risk reductions
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(RRRs) in VTE events with rivaroxaban against enoxaparin of
70–79% (p < 0.001) following THR and 49% following TKR
(p < 0.001). However, the effect of rivaroxaban relative to alter-
native prophylaxes is also important, including those presently in
development. A systematic literature review identiﬁed RCTs
comparing enoxaparin with warfarin, fondaparinux or dabigat-
ran in THR or TKR. Indirect comparisons of rivaroxaban to
each were conducted, using enoxaparin as common comparator.
Whenever the comparison included more than three studies,
a meta-regression was performed. Results presented are RRRs
from those analyses. RESULTS: Rivaroxaban showed statisti-
cally signiﬁcant reductions in the incidence of key endpoints. In
THR, when compared with fondaparinux, rivaroxaban was
associated with RRRs of 56% in total VTE (p = 0.015) and 89%
(p = 0.015) in symptomatic VTE. When compared with dabiga-
tran, RRRs with rivaroxaban were 86% (p = 0.0018) in symp-
tomatic VTE and 77% (p < 0.001) in total VTE. Similarly, when
compared with warfarin, the RRR in symptomatic VTE with
rivaroxaban was 92% (p = 0.003). In TKR, rivaroxaban pro-
duced 67% (p < 0.001) and 66% (p < 0.001) reductions in total
VTE and deep vein thrombosis (DVT) respectively, versus war-
farin, and 50% (p < 0.001) reductions in total VTE and DVT
versus dabigatran. No other statistically signiﬁcant differences
were found. Importantly for a new anticoagulant, there were
no increases in major bleeding so safety endpoints are unlikely
to inﬂuence cost-effectiveness. CONCLUSION: Rivaroxaban
reduced the incidence of overall or symptomatic VTE events
relative to alternative prophylaxes without increased major
bleeding, reﬂecting a better clinical proﬁle. These risk reductions
may have implications for cost-effectiveness analyses.
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OBJECTIVE: To estimate the cost-effectiveness of the use of
drug-eluting stent compared to bare-metal stent in a cohort of
patients with coronary disease in the Social Security Mexican
Institute (IMSS). METHODS: Cost-effectiveness in a cohort of
patients with ischemic disease with indication of PCI (Percuta-
neous Coronary Intervention). The measure of effectiveness was
the rate of clinical success without major cardiovascular adverse
events. The cost and effectiveness of the treatment were
obtained from clinical follow-up of the cohort from 104
patients in the Cardiology Hospital of IMSS. The micro-costing
technique was used, and the costs come from bases institutional
costs. The results are expressed in US dollars (US$) in 2007.
Given the time horizon of the study (12 months), the discount
rate was not applie. We performed a sensitivity analysis proba-
bilistic, and I think the curve of acceptability. RESULTS: The
61.5% of patients in the cohort used bare-metal stent and
38.5% drug-eluting stent, drug-eluting stent showed the highest
average cost per patient US$15,452.9  12,996.8 compared
with bare-metal stent US$14,254.4  10,826.5. However, the
effectiveness drug-eluting stent found were 97.44% (95%
92.48–100) regarding a bare-metal stent 81.67% (95% CI
71.88–91.46). The RCE was US$17,453.5 in the case of drug-
eluting stent and US$15,829.6 with bare-metal stent, the RCEI
was US$7419. The acceptability curve shows that the treatment
of drug-eluting stent becomes the dominant cost-effectiveness
alternative from WTP US$15,109.9. The probabilistic analysis
shows that drug-eluting stent is more cost effective when it
exceeds US$21,153.8 WTP per patient. CONCLUSION: Drug-
eluting stent is an alternative treatment interventional revascu-
larization with better outcomes in health, and depending from
the availability to pay can be a cost-effectiveness alternative to
the institution.
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OBJECTIVE: To consider the cost-effectiveness of POM statins,
OTC statin and plant sterol/stanol products from the perspective
of middle aged males when used according to current UK guid-
ance for the primary prevention of CVD. METHODS: We used
a Markov-Model to obtain the outcomes for an illustrative
cohort up to 100 years old or death, whichever come sooner. For
the base-case we assumed that all would receive POM statins
from 70 years old and all had to pay for their prescription charge
up to 59 years. The main outcomes for effects were QALYs
(quality-adjusted life-years) and LYG (Life Years Gained). The
main costs included were prescription charges, product costs,
travel costs and gross weekly incomes. The NICE technology
assessment report “Statins for the Prevention of Coronary
Events” published in 2005 was used for transition probabilities
and utility values. Updated costs for 2007 values extracted from
NHS and “HM Revenue & Customs” databases, and average
retail prices of the UK market. RESULTS: Estimated discounted
incremental cost/QALYs were 2970.63, 8026.37 and
16,536.84 for POM statins, OTC statin and plant stanol/sterol
products, respectively. Estimated discounted incremental cost/
LYGs were 5339.02, 14,458.69 and 30,076.96, respec-
tively. Cost/QALYs ranged from 1318.03 to 7854.44,
4289.46 to 11,763.28 and 3961.10 to 29,112.59 for
POM statins, OTC statin and plant sterol/stanol products,
respectively in the univariate sensitivity analyses. CONCLU-
SION: From the patient’s viewpoint, the most cost-effective
intervention is a POM statin (2970.63/QALY). There are con-
siderable differences between the most (POM statins) and the
least (plant sterol/stanol products) cost-effective interventions.
However, for individual patients non-eligibility for free prescrip-
tion or a strong desire to avoid medicalising disease prevention
may overturn the main results.
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OBJECTIVE: To study preventive technologies economic efﬁ-
ciency for patients with cardiovascular diseases in Russia.
METHODS: The study consisted of two parts. The ﬁrst part
involved 303 hypertensive patients without serious s complica-
tions. The second part involved 100 patients with coronary heart
disease (CHD). In both substudies, patients were randomized to
treatment and control groups. Patients of the treatment group
participated in a structured education program for hypertensive
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